Nuvation Bio Inc. (NUVB) IBTROZI Showing Promise in Non-Small Cell Lung Cancer Trials

Nuvation Bio Inc. (NYSE:NUVB) is one of the best healthcare penny stocks to buy now. On September 7, the company delivered new and positive updated results from pivotal Phase 2 TRUST-1 and TRUST-II studies evaluating IBTROZI (taletrectinib) in non-small cell lung cancer (NSCLC).

Nuvation Bio Inc. (NUVB) IBTROZI Showing Promise in Non-Small Cell Lung Cancer Trials

Billion Photos/Shutterstock.com

The updated findings show notable progression-free survival results, affirming responses with IBTROZI remain durable. The results support the recent approval of the drug in the US, adding a new option for patients with non-small cell lung cancer.

“These long-term data emphasize impressive PFS and durability of response, with a tolerable and manageable safety profile that helps patients stay on therapy so they can continue to benefit. We remain excited about the promise of IBTROZI and look forward to further data generation from continued follow-up in the TRUST studies,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio.

Nuvation Bio Inc. (NYSE:NUVB) is a global biopharmaceutical company focused on developing novel, differentiated therapies to address significant unmet needs in oncology, with a focus on difficult-to-treat cancers. Their pipeline includes candidates for ROS1+ non-small cell lung cancer (taletrectinib), IDH1-mutant glioma (safusidenib), and other advanced solid tumors (NUV-1511 and NUV-868).

While we acknowledge the potential of Nuvation Bio Inc. (NYSE:NUVB) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NUVB and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Best AI Stocks to Buy Under $5 and 12 Best Beginner Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.